瑞舒伐他汀对不稳定型心绞痛患者血脂、超敏C反应蛋白及同型半胱氨酸的影响

目的评价瑞舒伐他汀辅治不稳定型心绞痛(UA)的疗效及其对血脂、超敏C反应蛋白(hs-CRP)和同型半胱氨酸(Hcy)水平的影响。方法将86例UA患者随机分为治疗组和对照组各43例。对照组给予阿司匹林、氯吡格雷抗血小板聚集及低分子肝素抗凝治疗;治疗组在对照组治疗基础上予瑞舒伐他汀10mg口服,每晚1次。2个月后比较2组临床疗效,并观察用药前后血脂、hs-CRP和Hcy水平的变化。结果治疗组总有效率为95.35%高于对照组的72.09%,差异有统计学意义(P<0.05)。治疗后2组TC、TG、LDL-C水平均较治疗前明显下降(P<0.01),HDL-C较治疗前明显升高(P<0.01),治疗组较对照组变化更为明显(P<0.01或P<0.05)。与治疗前比较,2组治疗后hs-CRP水平明显下降(P<0.01),而Hcy水平仅治疗组较治疗前明显下降(P<0.01)。治疗后治疗组hs-CRP和Hcy水平均低于对照组(P<0.05或P<0.01)。结论瑞舒伐他汀可提高UA的疗效,能降低血中hs-CRP和Hcy水平,从而降低UA及动脉粥样硬化危险因素。

Effect of rosuvastatin on the levels of lipid,hypersensitive C-reactive protein and homocystein in patient with unstable angina

Objective To investigate the effect of rosuvastat on the levels of the blood lipid,highsensitivity C-reactive protein（hs-CRP）and homocysteine（Hcy） in patients with unstable angina（UA）.Methods 86 patients with UA were divided randomly into treatment group and control group.Control group was given aspirin,hydrogen clopidogrel and low molecular heparin.Based on control group,treatment group was treated with rosuvastatin 10mg orally,1 time per night.The changes of blood lipid,hs-CRP and Hcy level of two groups were compared 2 months after treatment.Results The total effective rate of treatment group was 95.35% higher than 72.09% of control group,the difference was statistically significant（P〈0.05）.After treatment,TC,TG and LDL-C level of two groups were lower than those before treatment（P〈0.01）,HDL-C was higher than that before treatment（P〈0.01）,treatment group changed more significantly than control group（P〈0.01 or P〈0.05）.Compared with before treatment,hs-CRP level of two groups decreased significantly（P〈0.01）,and Hcy level only treatment group decreased significantlythan before treatment（P〈0.01）.After treatment,hs-CRP and Hcy levels of treatment group were lower than control group（P〈0.05 or P〈0.01）.Conclusion Rosuvastatin can reduce blood levels of hs-CRP and Hcy,thus reduce risk factors of the unstable angina and atherosclerosis.